Overview

A Study of LY2484595 in Japanese Subjects

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if 12 weeks of treatment with LY2484595 administered as a monotherapy will significantly increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) in Japanese participants.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Atorvastatin
Atorvastatin Calcium
Evacetrapib